Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720360 | 0.90 | MGLL (0.32) | — | |
| SCHEMBL4538380 | 0.89 | USP2 (0.40) | USP2SMN1; SMN2GPR119PKMJAK2 | |
| SCHEMBL4542010 | 0.80 | USP2 (0.43) | USP2SMN1; SMN2GPR119ACACBPIK3R1 | |
| SCHEMBL4538704 | 0.78 | USP2 (0.42) | USP2SMN1; SMN2GPR119ACACBPIK3R1 | |
| SCHEMBL4537163 | 0.78 | USP2 (0.41) | USP2SMN1; SMN2GPR119ACACBJAK2 | |
| SCHEMBL17324893 | 0.77 | SIGMAR1 (0.45) | USP2SMN1; SMN2GPR119ACACB | |
| SCHEMBL14720194 | 0.76 | USP2 (0.40) | USP2SMN1; SMN2GPR119ACACBJAK2 | |
| SCHEMBL20555552 | 0.74 | USP2 (0.39) | USP2SMN1; SMN2GPR119ACACBJAK2 | |
| SCHEMBL15544785 | 0.74 | USP2 (0.40) | USP2SMN1; SMN2GPR119ACACB | |
| SCHEMBL25275634 | 0.73 | USP2 (0.47) | USP2SMN1; SMN2GPR119ACACBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744333-B1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| US-9084794-B2 | Fatty acid synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property (No2) Limite (GB) | 2014-07-10 | — | — | US | disclosed |
| EP-2744333-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014008223-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013028447-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS2, FADS1 | USP2 3234/4885SMN1; SMN2 4692/4885GPR119 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.